111217-18-6

Basic information

• Product Name: methyl 2,3,5-trichloro-6-hydroxybenzoate
• Synonyms: methyl 2,3,5-trichloro-6-hydroxybenzoate
• CAS NO: 111217-18-6
• Molecular Formula: C₈H₅Cl₃O₃
• Molecular Weight: 255.48
• Mol File: 111217-18-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: methyl 2,3,5-trichloro-6-hydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 2,3,5-trichloro-6-hydroxybenzoate(111217-18-6)
• EPA Substance Registry System: methyl 2,3,5-trichloro-6-hydroxybenzoate(111217-18-6)

Safety Data

• Hazardous Substances Data: 111217-18-6(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 40932-60-3 3,5,6-Trichloro-2-hydroxybenzoic acid 
• 546-68-9 titanium(IV) isopropylate 

Relevant articles and documents

Synthesis and biological evaluation of novel 5,6,7-trimethoxy flavonoid salicylate derivatives as potential anti-tumor agents

5,6,7-Trimethoxy flavonoid salicylate derivatives were designed by the joining of three important pharmacophores (TMP, flavonoid, and SA) according to the combination principle. A series of novel trimethoxy flavonoid salicylate derivatives were synthesized and their in vitro anti-tumor activities were evaluated. Among these derivatives, compound 7f exhibited excellent antiproliferative activity against HGC-27 cells and MGC-803 cells with IC50 values of 10.26 ± 6.94 μM and 17.17 ± 3.03 μM, respectively. Subsequently, the effects on cell colony formation (clonogenic survival assay), cell migration (wound healing assay), cell cycle distribution (PI staining assay), cell apoptosis (Hoechst 33258 staining assay and annexin V-FITC/PI dual staining assay), lactate level (lactate measurement), microtubules disarrangement (immunofluorescence staining analysis) and docking posture (molecular docking simulation) were determined. Further western blot analysis confirmed that compound 7f could effectively down-regulate the expression of glycolysis-related proteins HIF-1α, PFKM and PKM2 and tumor angiogenesis-related proteins VEGF. Overall, these studies suggested that compound 7f, as the representative compound of those, might be a promising candidate for the treatment of gastric cancer and deserved the further studies.

Process for preparing esters of 3,5,6-trichlorosalicyclic acid

An improved process for the synthesis of esters of 3,5,6-trichlorosalicylic acid in quantitative yield comprises reacting the acid with an alcohol under distillation conditions in the presence of a titanium ester or chelate catalyst, whereby byproduct ether formation from the alcohol is suppressed. The process is especially applicable to a process by which salicylic acid is chlorinated first in concentrated sulfuric acid and then with iodine catalyst to make the trichlorosalicylic acid which is extracted and then reacted with an alcohol and a titanium catalyst to make the ester.